Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.35 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.33 |
| ▸ | SIGMAR1 known ✓ | Q99720 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL53117 | 0.98 | CYP1A2 (1.00) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| Carbimide SCHEMBL10416395 | 0.94 | CYP1A2 (0.91) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| Chloromethane SCHEMBL11328216 | 0.94 | CYP1A2 (0.91) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| Sulfuric Acid SCHEMBL31183034 | 0.90 | CYP1A2 (0.84) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| SCHEMBL29648226 | 0.89 | CYP1A2 (0.82) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| SCHEMBL2729317 | 0.88 | CYP1A2 (0.80) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| SCHEMBL11036329 | 0.84 | CYP1A2 (0.73) | CYP1A2EPHX1HIF1ACYP2C9ALDH1A1 | |
| Ethylbenzene SCHEMBL7167647 | 0.83 | CYP1A2 (0.71) | CYP1A2CYP2C9ALDH1A1KDM4ESIGMAR1 | |
| SCHEMBL3293863 | 0.83 | CYP1A2 (0.72) | CYP1A2EPHX1HIF1ACYP2C9GAA | |
| P-Xylene SCHEMBL3752326 | 0.82 | CYP1A2 (0.70) | CYP1A2CYP2C9ALDH1A1GLATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1090637-C | Crosslinked cinnamic acid hyaluronic acid derivatives and process for producing the same | SEIKAGAKU KOGYO CO LTD (JP) | 2002-09-11 | — | — | CN | claimed |
| US-12090248-B2 | Crosslinked hyaluronic acid, hyaluronic acid hydrogel, and method for producing crosslinked hyaluronic acid and hyaluronic acid hydrogel | HANMI PHARM. CO., LTD. (KR) | 2024-09-17 | — | — | US | disclosed |
| CN-113166434-B | Crosslinked hyaluronic acid, hyaluronic acid hydrogel and preparation method thereof | 韩美药品株式会社 | 2024-07-09 | — | — | CN | disclosed |
| CN-113166434-A | Cross-linked hyaluronic acid, hyaluronic acid hydrogel and preparation method thereof | 韩美药品株式会社 | 2021-07-23 | — | — | CN | disclosed |
| WO-2020116999-A1 | CROSSLINKED HYALURONIC ACID, HYALURONIC ACID HYDROGEL, AND METHOD FOR PRODUCING CROSSLINKED HYALURONIC ACID AND HYALURONIC ACID HYDROGEL | 한미약품 주식회사 | 2020-06-11 | — | — | WO | disclosed |
| US-9616087-B2 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2017-04-11 | — | — | US | disclosed |
| US-9301972-B2 | Hyaluronic acid derivatives | SEIKAGAKU CORPORATION (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150283169-A1 | PHARMACEUTICAL AGENT HAVING LONG-LASTING EFFECT OF TREATING ARTHRITIC DISORDERS | SEIKAGAKU CORPORATION (JP) | 2015-10-08 | — | — | US | disclosed |
| CN-103356694-B | The long-acting medicament for the treatment of of arthritis disease | SEIKAGAKU KOGYO CO., LTD. (JP) | 2015-09-02 | — | — | CN | disclosed |
| EP-2910248-A1 | Pharmaceutical agent having long-lasting effect of treating arthritic disorders | SEIKAGAKU CORPORATION (JP) | 2015-08-26 | — | — | EP | disclosed |
| CN-1245812-A | Cinnamic acid derivative | SEIKAGAKU KOGYO CO LTD (JP) | 2000-03-01 | — | — | CN | disclosed |
| US-6031017-A | DIMERIZATION BY ULTRAVIOTLET RADIATION TO FORM A CYCLOBUTANE RING AND A NETWORK HAVING CONTROLLED BIOCOMPATABILITY AND BIODEGRADATION; STORAGE STABILITY; PARENTAL INJECTIONS; PURITY; KITS | SEIKAGAKU CORPORATION (JP) | 2000-02-29 | — | — | US | disclosed |
| US-6025444-A | HYALURONIC ACID POLYSACCHARIDE DERIVATIVE; PHOTODIMERIZABLE, CROSSLINKABLE | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 2000-02-15 | — | — | US | disclosed |
| CN-1207744-A | Photocured cross-linked-hyaluronic acid gel and method of preparation thereof | SEIKAGAKU KOGYO CO LTD (JP) | 1999-02-10 | — | — | CN | disclosed |
| EP-0861270-A1 | PHOTOCURED CROSS-LINKED-HYALURONIC ACID GEL AND METHOD OF PREPARATION THEREOF | SEIKAGAKU CORPORATION (JP) | 1998-09-02 | — | — | EP | disclosed |
| US-5789462-A | PHOTOPOLYMERIZATION | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1998-08-04 | — | — | US | disclosed |
| WO-1997018244-A1 | PHOTOCURED CROSS-LINKED-HYALURONIC ACID GEL AND METHOD OF PREPARATION THEREOF | SEIKAGAKU CORPORATION (JP) | 1997-05-22 | — | — | WO | disclosed |
| EP-0763754-A2 | Photocured crosslinked-hyaluronic acid contact lens | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1997-03-19 | — | — | EP | disclosed |
| CN-1133834-A | cinnamic acid derivatives | SEIKAGAKU KOGYO CO LTD (JP) | 1996-10-23 | — | — | CN | disclosed |
| EP-0713859-A2 | Cinnamic acid derivatives, photocrosslinkable cinnamic acid-polymer derivative and crosslinked cinnamic acid polymer derivatives | SEIKAGAKU KOGYO KABUSHIKI KAISHA (SEIKAGAKU CORPORATION) (JP) | 1996-05-29 | — | — | EP | disclosed |